Gadicke Ansbert's Form 4 filing
Aktis Oncology, Inc. (AKTS) · filed Jan 14, 2026
- Accession no.
- 0001231919-26-000055
- Filed
- Jan 14, 2026, 6:17 PM ET
- Trade date
- Jan 12, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market purchases total $20.0M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gadicke AnsbertCIK 0001134655 | 10% Owner |
| MPM Asset Management LLCCIK 0001263048 | 10% Owner |
| Oncology Impact Private Investment Fund 2, L.P.CIK 0002104306 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | Common Stock | CConversionAcquired | +1,314,262 | –F2 | – | 1,655,971 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionAcquired | +5,914,197 | –F2 | – | 7,570,168 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionAcquired | +1,577,119 | –F2 | – | 9,147,287 | Indirect | |
| Jan 12, 2026 | Common Stock | PPurchaseAcquired | +1,112,777 | $18.00 | +$20,029,986 | 10,260,064 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | Common Stock | CConversionDisposed | −1,314,262 | $0.00F2 | $0 | 0 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionDisposed | −5,914,197 | $0.00F2 | $0 | 0 | Indirect | |
| Jan 12, 2026 | Common Stock | CConversionDisposed | −1,577,119 | $0.00F2 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date.
Referenced by the price of 3 transactions in Table I and 3 transactions in Table II.
Remarks
This filing is 1 of 2 identical filings due to limitations on number of Reporting Persons. See Form 4 filed by MPM BioVentures 2018, L.P.